<table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="tblu15" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Pooled SD</th><th>Effect size d</th><th>A priori power</th><th>Group 1 sample size</th><th>Group 2 sample size</th></tr></thead><tbody><tr><td>LM-4175 only</td><td>LM-4175 + Cav1 WT pMEFs</td><td>7.03</td><td>2.588043</td><td>83.5%<xref ref-type="table-fn" rid="tblfn5">*</xref></td><td>4</td><td>4<xref ref-type="table-fn" rid="tblfn5">*</xref></td></tr><tr><td>LM-4175 + Cav1 WT pMEFs</td><td>LM-4175 + Cav1 KO pMEFs</td><td>6.04</td><td>2.648198</td><td>85.0%<xref ref-type="table-fn" rid="tblfn6">&#8224;</xref></td><td>4<xref ref-type="table-fn" rid="tblfn6">&#8224;</xref></td><td>4<xref ref-type="table-fn" rid="tblfn6">&#8224;</xref></td></tr></tbody></table><table-wrap-foot><fn id="tblfn5"><label>*</label><p>7 tumors will be used based on the fibronectin fiber orientation analysis making the power 94.4%.</p></fn><fn id="tblfn6"><label>&#8224;</label><p>7 tumors will be used based on the fibronectin fiber orientation analysis making the power 99.3%.</p></fn></table-wrap-foot></table-wrap>